Exelixis | EXEL - Reddito Netto





Reddito Netto Cambiamento Data
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Amgen USD 1.33B 1.88B 2025-12
AstraZeneca USD 2.33B 207M 2025-12
Bayer EUR -3.76B 2.79B 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Cytokinetics USD -183.03M 123.15M 2025-12
Eisai JPY 17.18B 7.02B 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Exelixis USD 193.58M 8.73M 2025-09
Genmab DKK 336M 141M 2025-06
Glaxosmithkline GBP 2.71B 1.27B 2025-09
Incyte USD 299.28M 124.89M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
MacroGenics USD -14.16M 30.98M 2025-12
Merck USD 2.96B 2.82B 2025-12
Moderna USD -200M 625M 2025-09
Nektar Therapeutics USD -37.06M 15.31M 2024-09
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 3.93B 96M 2025-09
Pfizer USD -1.65B 5.19B 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sanofi EUR -801M 3.6B 2025-12
Takeda JPY 103.64B 115.44B 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
Xencor USD -6.65M 626K 2025-12